[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342178-105":59,"doc-detail-342178-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","adagrasib-in-the-treatment-of-kras-pg12c-positive-advanced-nsclc-design-development-and-place-in-therapy","Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC - Design, Development and Place in Therapy","","KRAS mutations occur in 25–30% of NSCLC and drive oncogenesis through persistent MAPK/ERK pathway activation. Although historically considered “undruggable”, targeted KRAS p.G12C inhibitors have been developed, including sotorasib and adagrasib. This review centers on adagrasib, the second KRAS p.G12C inhibitor to receive FDA regulatory approval, summarizing its study design, developmental evidence, and current therapeutic role in KRAS p.G12C positive advanced NSCLC. It also contextualizes challenges such as CNS metastasis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/adagrasib-in-the-treatment-of-kras-pg12c-positive-advanced-nsclc-design-development-and-place-in-therapy/342178/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/adagrasib-in-the-treatment-of-kras-pg12c-positive-advanced-nsclc-design-development-and-place-in-therapy/342178.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the significance of KRAS mutations in NSCLC?","Question",{"text":112,"@type":113},"KRAS mutations are present in roughly 25–30% of NSCLC and promote oncogenesis by persistently activating MAPK/ERK signaling. This makes KRAS a key molecular target for therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are KRAS p.G12C inhibitors important?",{"text":117,"@type":113},"KRAS p.G12C inhibitors, such as sotorasib and adagrasib, were developed to target a mutation previously considered “undruggable”. The article highlights adagrasib as FDA-approved and focuses on its development and therapeutic role.",{"name":119,"@type":110,"acceptedAnswer":120},"How does brain metastasis relate to KRAS-mutated NSCLC?",{"text":121,"@type":113},"Lung cancer is a major cause of brain metastases, and up to 25–50% of patients with KRAS-mutated NSCLC are diagnosed with brain metastases. CNS failures are reported more frequently, and brain metastasis is linked to worse overall survival and quality of life.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342178,1790818283,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Drug Design, Development and Therapy Dovepress  \n Open Access Full Text Article REVIEW  \nAdagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy  \nBrian Warnecke 1 , Misako Nagasaka 1 , 2  \n1Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA; 2Department of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan  \nCorrespondence: Misako Nagasaka, Department of Medicine, University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USA, Email [nagasakm@hs.uci.edu](nagasakm@hs.uci.edu)  \n\n| Abstract: One of the most common mutations seen in lung cancers are mutations in Kristen Rat Sarcoma Viral Oncogene Homolog (KRAS), observed in 25–30% of patients with NSCLC. Mutations in KRAS result in oncogenesis via persistent activation of the MAPK/ERK pathways. Although once thought to be “undruggable”, KRAS p.G12C inhibitors such as sotorasib and adagrasib have been developed. This paper focuses on adagrasib, the second KRAS p.G12C inhibitor to obtain regulatory approval by the FDA and describes the details on its study design, development and current place in therapy.\u003Cbr>Keywords: Kristen Rat Sarcoma Viral Oncogene Homolog, sotorasib, AMG510, MRTX849, KRYSTAL, CodeBreaK, brain penetration |\n| --- |\n| Background\u003Cbr>Oncogenic driver mutations are detected in approximately 60% of non-small cell lung cancers (NSCLC) .1 Next generation sequencing (NGS) enables the identification of mutations with therapeutic implications, allowing for the use of targeted agents.2–4 The most common mutation, however, are mutations in Kristen Rat Sarcoma Viral Oncogene Homolog (KRAS) which are seen in approximately 25–30% of patients with NSCLC.1,5\u003Cbr>Notably, there is a vast heterogeneity within the subtypes of KRAS-mutated NSCLC, and prevalence rates can vary geographically. The most common KRAS mutation is the p.G12C mutation, characterized by a glycine-to-cysteine mutation at codon 12. This is estimated to be seen in 40% of patients with KRAS-mutated NSCLC. The next most common KRAS mutations are G12V (19%), and G12D (15%) .5,6 KRAS mutations have higher frequency in adenocarcinomas than squamous cell carcinomas, 37.2% vs 4.4%, respectively.5 Patients who are current or former smokers are also more likely to harbor KRAS mutations compared to non-smokers, one study reporting 34% vs 6%, respectively. Within the smoking cohort, KRAS p.G12C is the most common mutation seen and observed in 41% of those patients.7\u003Cbr>The oncogenesis ofKRAS-mutated NSCLC revolves around the MAPK/ERK biochemical cascade. KRAS is one of three isoforms within the RAS group of oncogenes. It is a GTPase protein located on the cell membrane and functions to directly interact with the downstream signaling MAPK/ERK pathways, which is vital for cell survival, growth, and differentiation.8 In KRAS mutant cells, GTP-bound KRAS remains persistently active, triggering a downstream cascade of phosphorylation and kinase activation of MEK and ERK. ERK kinases translocate to the nucleus of the cell to aid in vital cell functions. In RAS-mutant human cancer cells, these proteins exhibit single amino-acid replacements primarily residing at G12 or Q61 . Thus, these RAS-mutant cells remain GTP-bound, leading to persistently activated signaling of their downstream cascade allowing for oncogenesis.9\u003Cbr>Lung cancer is the main etiology of brain metastases, accounting for 40–50% of all brain metastases.10 Up to 25–50% of patients with KRAS-mutated NSCLC are diagnosed with brain metastases.11, 12 The development of brain metastases |\n\nReceived: 28 August 2024  \nAccepted: 25 November 2024  \nPublished: 5 December 2024  \nDrug Design, Development and Therapy 2024:18 5673–5683 5673  \n© 2024 Warnecke and Nagasaka. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are a","cbCaikf7PKT25pkE","https://ap.wps.com/l/cbCaikf7PKT25pkE","pdf",434505,11,"English","# Background\n# Early Development of KRAS p.G12C Inhibitors","[{\"question\":\"What is the significance of KRAS mutations in NSCLC?\",\"answer\":\"KRAS mutations are present in roughly 25–30% of NSCLC and promote oncogenesis by persistently activating MAPK/ERK signaling. This makes KRAS a key molecular target for therapy.\"},{\"question\":\"Why are KRAS p.G12C inhibitors important?\",\"answer\":\"KRAS p.G12C inhibitors, such as sotorasib and adagrasib, were developed to target a mutation previously considered “undruggable”. The article highlights adagrasib as FDA-approved and focuses on its development and therapeutic role.\"},{\"question\":\"How does brain metastasis relate to KRAS-mutated NSCLC?\",\"answer\":\"Lung cancer is a major cause of brain metastases, and up to 25–50% of patients with KRAS-mutated NSCLC are diagnosed with brain metastases. CNS failures are reported more frequently, and brain metastasis is linked to worse overall survival and quality of life.\"}]","Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC - Design, Development and Place in Therapy | PDF",1790045706,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cbe0fa3a9b20305438b6330de32979b6.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c675ce259bf75e55041c4e83fac39dc.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07eddcbd4baf6f3cb4c6834992d7e2f9.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ff5e9d9083399aefe561ed87357108e.webp",980,1268]